asal Cell Carcinoma Market Analysis Growth Factors and Competitive Strategies by Forecast 2032

The global basal cell carcinoma market size was valued at USD 6,700 million in 2021 and is projected to reach around USD 12,000 million in 2030 exhibiting a CAGR of 8.0% in the forecasted period. The higher prevalence of skin malignancies, product approval for the cure of basal cell carcinoma is also projected to boost the market. However, high prices for basal cell carcinoma treatment, interruption in accessing medical conditions, and after effects of the treatment and approval time for the drugs taking too long is hampering the growth of the market in the forecasted period.

The major factors attributing to the growth of the market are the growing prevalence of skin malignancies, a rise in several environmental factors that lead to further UV exposure, and a growing geriatric population that is more vulnerable to skin diseases. As per the March 2022 article issued by WCRFI, there are two major forms of skin cancer, namely melanoma, and non-melanoma. Squamous cell carcinoma and basal cell carcinoma are the maximum typical non-melanoma cancers. The 17th most prevalent cancer worldwide is cutaneous melanoma. In relations of prevalence, it ranks 15th among malignancies in women and 13th among cancers in men. In 2020, there were over 150,000 new cases of cutaneous melanoma. Also, as per an article issued by the American Academy of Dermatology Association in April 2022, skin cancer is the most prevalent type of cancer between Americans. As per the current projections, one in five Americans may have skin cancer at some about point in their lives. In the United States, a projected 9,500 people receive a skin cancer diagnosis every day. Above three million Americans are supposed to be affected yearly by nonmelanoma skin cancer (NMSC), which comprises basal cell carcinoma (BCC) and squamous cell carcinoma (SCC). Thus, the growing prevalence of skin cancer is anticipated to boost market demand for treatments, in turn strengthening the market’s growth.

Ever since the COVID-19 virus eruption in December 2019, the ailment has spread above 100 nations across the world and the World Health Organization has stated it a public health emergency. As per the World Health Organization’s report, the demonstration of coronavirus (COVID-19) has caused in over 256 million diseased individuals globally as of November 22, 2021. COVID-19 can disturb the budget in three main ways; by directly affecting manufacture and demand, by generating disruptions in distribution channels, and over its financial impact on organizations and financial markets. Owing to national lockdowns, several countries such as India, China, Saudi Arabia, UAE, Egypt, and others are facing difficulties with respects to conveyance of drugs from one place to another.

Furthermore, players operating in the global basal cell carcinoma market are facing main challenges on many fronts due to the COVID-19 pandemic. The major problems include supply of raw materials necessary for manufacturing drug preparations owing to indiscretions in transportation. Furthermore, distributors are undergoing unbalanced demand for products from the merchants due to a growth in the number of patients suffering from COVID-19 and other life threatening disorders.

Treatment Type Insights
Surgery held the largest share in the treatment type segment of basal cell carcinoma market in 2021 and is projected to grow at a significant CAGR during the forecast period. Basal cell carcinoma is maximum often treated with surgery to eradicate the cancer and few healthy tissue around it. Options might include: Surgical excision. In this process, the doctor slices out the tumorous lesion and a neighbouring boundary of healthy skin. Cost-efficiency of basal cell carcinoma operation and R&D events on better performing surgeries by key market businesses are further assisting in the growth of this segment.

Drugs segment held the second largest share in 2021, due to their benefits of cosmetic consequence which has been frequently shown to be greater to cryotherapy, and therefore, recommended as a treatment of choice for patients with numerous superficial or thin nodular BCCs, mostly if located at cosmetically vital locations. Surgery segment is set to be the fastest developing segment and is projected to register the highest CAGR during the forecast period, due to growing demand for effective and quicker treatment approaches which is done with the help of operations and growing awareness about its efficiency among people.

Distribution Channel Insights
Hospitals held the major share in the distribution channel segment of basal cell carcinoma market in 2021. For patients detected with basal cell carcinoma, the hospitals offer renowned specialists in skin cancer and dermatologic surgery which built a personalized treatment plan for patients which can comprise a number of choices that have been found to be very positive in treating BCC. The types include Cryosurgery, Mohs micrographic surgery, and electrodesiccation and curettage amongst others. As a result, people are appealed significantly to the cure done in hospitals. This has boosted the demand of this segment. Hospitals are forecasted to grow at the fastest rate with the highest CAGR during the forecast period 2020-2025, owing to their growing financial capability and more significant players investing in hospitals for therapies.

Region Insights
North America dominated the geography segment of basal cell carcinoma market in 2021 with a share of more than 40% in 2021, followed by Europe. Presence of developed healthcare infrastructure in countries such as the U.S., Canada, Mexico, and others, technical advancement in healthcare infrastructure, with better and innovative healthcare facilities rising prevalence of basal cell carcinoma, and growing key developments by market players have assisted in the growth of basal cell carcinoma market infrastructure in this region.
Europe held the second place in the regional share of the market, due to rising awareness about BCC and existence of well-developed healthcare infrastructure in this region.
However, Asia-Pacific is estimated to grow at the fastest rate during the forecasted period. This is due to fast growing budget of healthcare funds, entry of new market companies in the region and increasing disposable income of the population.

Key Companies Insights
The market for basal cell carcinoma is moderately competitive. With the rising applications of Basal cell carcinoma, new players are considering to enter the market. The companies are also involved in activities like joint ventures, acquisitions, partnerships, mergers, and collaborations. These activities aid in growing the effect of the players in the basal cell carcinoma market, ultimately boosting the market growth. 

Some of the key companies working in the global basal cell carcinoma market include:
• Merck & Co., Inc.
• Sun Pharmaceutical Industries Ltd.
• Novartis AG
• Bausch & Lomb Incorporated
• Allergan
• Perrigo Company plc
• Taro Pharmaceutical Industries Ltd.
• Provectus Biopharmaceuticals, Inc.
• F. Hoffmann-La Roche Ltd
• Sanofi
• Mylan N.V.
• Other players

Some of the Recent Developments:
• In May 2020, Sanofi announced that its Libtayo (cemiplimab) demonstrates clinically meaningful and durable replies in second-line advanced basal cell carcinoma.
• In May 2020, Provectus announced PV-10 STING agonist abstract at American Association for Cancer Research (AACR) 2020 Virtual Annual Meeting II.
• In July 2015, FDA approved Novartis drug Odomzo (sonidegib) for nearby advanced basal cell carcinoma (laBCC).

Segments
By Treatment Type
• Surgery
• Drugs
• Others

By Disease Indication
• Locally Advanced Basal Cell Carcinoma
• Metastatic Advance Basal Cell Carcinoma

By Therapy
• Topical Medication
• Oral Medication
• Injectable

By Distribution Channel
• Hospitals
• Research Institutes
• Cancer Diagnostic Centers
• Ambulatory Surgical Centers
• Retail Pharmacies

By Geography
• North America
o U.S.
o Canada
o Mexico
• Europe
o U.K.
o Germany
o France
o Italy
o Spain
o Russia
• Asia-Pacific
o Japan
o China
o India
o Australia
o South Korea
o ASEAN
• Latin America
o Brazil
o Argentina
o Colombia
• MEA
o South Africa
o Saudi Arabia
o UAE
o Egypt